Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling

UNAIDS. 2019. Global HIV & AIDS statistics—2019 fact sheet. http://www.unaids.org/en/resources/fact-sheet. Accessed 1 February 2018.

UNAIDS. 2018. The youth bulge and HIV. https://www.unaids.org/sites/default/files/media_asset/the-youth-bulge-and-hiv_en.pdf. Accessed 21 January 2020.

10.1186/s12977-018-0408-3

10.1097/QAI.0000000000001555

Pilkington V, Hill A, Hughes S, Nwokolo N, Pozniak A. 2018. How safe is TDF/FTC as PrEP? A systematic review and meta-analysis of the risk of adverse events in 13 randomised trials of PrEP. J Virus Erad 4:215–224.

10.1056/NEJMoa1011205

10.1056/NEJMoa1108524

10.1371/journal.pone.0200296

10.1126/science.aai9383

10.1093/infdis/jiw077

10.1080/09540121.2019.1612014

10.1056/NEJMoa1202614

10.1056/NEJMoa1402269

10.1097/QAI.0000000000000172

Chloe Orkin KA Hernández-Mora MG Pokrovsky V Overton ET Girard P-M Oka S Ronald D Dorey D Griffith S Margolis DA Williams PE Parys W Spreen W. 2019. Long-acting cabotegravir + rilpivirine for HIV maintenance: FLAIR week 48 results. Conf Retroviruses Opportunistic Infect abstr 140.

Susan Swindells J-F-V Richmond GJ Rizzardini G Baumgarten A Del Mar Masia M Latiff G Pokrovsky V Mrus JM Huang JO Hudson KJ Margolis DA Smith K Williams PE Spreen W. 2019. Long-acting cabotegravir + rilpivirine as maintenance therapy: ATLAS week 48 results. Conf Retroviruses Opportunistic Infect abstr 139.

10.1016/S0140-6736(17)31917-7

10.1016/S2352-3018(17)30068-1

10.3390/pharmaceutics11070315

10.1016/j.jconrel.2018.08.010

10.1128/AAC.00656-15

Su JT Simpson SM Sung S Tfaily EB Veazey R Marzinke M Qiu J Watrous D Widanapathirana L Pearson E Peet MM Karunakaran D Grasperge B Dobek G Cain CM Hope T Kiser PF. 2019. A subcutaneous implant of tenofovir alafenamide fumarate causes local inflammation and tissue necrosis in rabbits and macaques. bioRxiv doi:10.1101/775452.

10.1016/j.antiviral.2015.11.009

Gilead Sciences. 2019. Gilead statement on commitment to advancing descovy for PrEP™ study in cisgender women & adolescent females.

10.1007/s00228-018-2513-6

10.1002/cpt.1227

Jenna Yager KB Castillo-Manchilla J Morrow M Ibrahim M Mchugh C Bushman L Kiser J Mawhinney S Anderson P. Tenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy. http://regist2.virology-education.com/presentations/2019/20AntiviralPK/30_Yager.pdf.

10.1089/apc.2018.0177

10.1128/AAC.00005-16

10.1002/jps.24014

Gatto G Girouard N Brand RM Johnson L Marzinke M Rowshan S Engstrom JC McGowan I Demkovich Z Lueke E van der Straten A. 2018. Pharmacokinetics of tenofovir alafenamide by subcutaneous implant for HIV PREP. Conf Retroviruses Opportunistic Infect abstr 486.

Manjula G, Mariana R-C, Debbie S, Moss JA, Paul W, Chris B, Dana W, Udayan C, Angel G, Joseph K, Gallay PA, Massoud M, Vincent KL, Marzinke MA, Hendrix CW, Baum MM. 2018. Multispecies in vivo evaluation of subdermal implants delivering tenofovir alafenamide: of mice, dogs and sheep. AIDS Res Hum Retroviruses 34:107.

10.1007/s40262-014-0227-1

10.2165/00003088-200342100-00002

CDC. 2016. Anthropometric reference data for children and adults: United States 2011–2014. https://www.cdc.gov/nchs/data/series/sr_03/sr03_039.pdf. Accessed 17 October 2019.

10.3109/10408444.2012.709225

10.1016/s0378-5173(99)00147-7

European Medicines Agency. 2016. Assessment report: Vemlidy. https://www.ema.europa.eu/en/documents/assessment-report/vemlidy-epar-public-assessment-report_en.pdf. Accessed 4 July 2019.

10.2165/00003088-200847040-00004

10.1002/jps.10005

10.1093/infdis/jiy726

10.1097/QAI.0000000000001699

10.1093/jac/dkx064

DrugBank. 2019. Tenofovir alafenamide. https://www.drugbank.ca/drugs/DB09299. Accessed 29 July 2019.